{"entity":{"id":"abalos-therapeutics","kind":"company","name":"Abalos Therapeutics","aka":[],"tldr":"Abalos Therapeutics is testing a modified virus, given into a vein, that is designed to switch on the immune system inside tumours without destroying the infected cells. Its first medicine, ABX-001, is in an early trial for people with advanced solid tumours.","summary":"Abalos Therapeutics GmbH, based in Düsseldorf, Germany, develops arenavirus-based immunotherapies built on lymphocytic choriomeningitis virus (LCMV), which it describes as a non-lytic viroimmunotherapy that replicates in cancer cells and antigen-presenting cells to trigger innate and adaptive immune responses inside the tumour (its AdaptInnate approach). The lead candidate ABX-001 entered a first-in-human, open-label, dose-escalation phase 1 study given as a single intravenous dose in about 18 patients with refractory or relapsed advanced solid tumours (EUCT 2024-512403-39-01); the company announced the first patient dosed on 23 October 2025. The ClinicalTrials.gov record, NCT07231458, also covers ABX-001 combined with pembrolizumab. Its first registered cancer trial, NCT07231458, was posted on ClinicalTrials.gov in November 2025. The company launched in October 2019 with a EUR 12 million Series A, and an extension led by Seventure Partners in October 2021 brought the Series A to EUR 43 million (USD 50 million); other investors named by the company include Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds, NRW.BANK, Gründerfonds Ruhr, Coparion and Hx Bio Ventures. It also received EUR 1.2 million from Germany's KMU-innovativ programme.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://abalos-tx.com/"},{"label":"First patient dosed with ABX-001, October 2025","url":"https://abalos-tx.com/wp-content/uploads/2025/10/20251023_Abalos_PR_FPI_ABX-001_Final.pdf"},{"label":"ClinicalTrials.gov: phase 1 trial of ABX-001 alone and with pembrolizumab (NCT07231458)","url":"https://clinicaltrials.gov/study/NCT07231458"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website; its 2021 release says it launched in October 2019.","The 2019 Series A release was listed on the company's news page but its text was not read; the EUR 12 million figure comes from the news page headline.","ABX-001 is described by the company as non-lytic, so it is not linked to the oncolytic virus record.","Company website and press releases read on 29 October 2026."],"hq":"Düsseldorf","country":"DE","companyType":"biotech","website":"https://abalos-tx.com/","stage":"growth","investors":[],"funding":[{"round":"Series A","year":2019,"source":"https://abalos-tx.com/wp-content/uploads/2019/10/20191015_Abalos_Series-A_EN_FINAL.pdf","note":"EUR 12 million launch round, as titled on the company's news page."},{"round":"Series A extension","year":2021,"amountUsd":50000000,"source":"https://abalos-tx.com/wp-content/uploads/2021/10/20211014_Abalos-Series-A-Extension_ENG_Final.pdf","note":"EUR 32.5 million extension led by Seventure Partners bringing the Series A total to EUR 43 million (USD 50 million); the USD figure is the round total stated in the release."}]},"route":"/companies/abalos-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}]}}